Daptomycin received its initial approval from the U.S. Food and Drug Administration (FDA) on September 1, 2003. It was first approved under the brand name Cubicin

Daptomycin treats complicated skin and skin structure infections (cSSSI) and bloodstream infections caused by certain gram-positive bacteria, including vancomycin-resistant enterococcus (MRSA) and methicillin-resistant staphylococcus VRE.

Daptomycin is administered intravenously (IV) by a healthcare professional. The lyophilized powder is reconstituted with sterile water to prepare the solution for IV infusion. The recommended dosage and infusion rate vary based on the type and severity of the infection, as well as the patient's weight and kidney function. This medication is usually given once daily. 

Common side effects of daptomycin include nausea, headache, diarrhea, and vomiting. Less frequently, some patients may experience muscle pain or weakness, indicating a rare condition called rhabdomyolysis. Additionally, allergic reactions to daptomycin, though uncommon, can manifest as skin rashes, itching, swelling, severe dizziness, or difficulty breathing, requiring immediate medical attention.

Daptomycin use may be associated with muscle-related side effects, including muscle pain, weakness, and, in rare cases, rhabdomyolysis. Allergic reactions, eosinophilic pneumonia, and potential interactions with statins and calcium-containing solutions have also been reported. The safety during pregnancy and breastfeeding has not been fully established. Prolonged or inappropriate use may lead to bacterial resistance. It may rarely cause a decrease in platelet counts (thrombocytopenia). Using it may increase the risk of developing Clostridium difficile-associated diarrhea, a potentially severe and life-threatening infection. Its effect on the cell membrane may lead to potential neuromuscular effects, such as tingling or numbness. This medication has been associated with rare cases of eosinophilic pneumonia, a condition characterized by an increase in certain white blood cells in the lungs.

Patients with pre-existing muscle disorders should be closely monitored, and immediate medical attention is required if severe allergic reactions or eosinophilic pneumonia symptoms occur. Patients should be monitored for neuromuscular effects and infusion-related reactions. Patients should report any concerning symptoms to their healthcare provider promptly. Regular blood counts should be performed in patients at risk for this condition. If severe diarrhea occurs during or after treatment, medical attention should be sought immediately.  Patients with pre-existing neuromuscular conditions should be closely monitored during treatment. Patients who experience cough, fever, or difficulty breathing should seek medical attention promptly.

When using daptomycin, it is essential to follow the prescribed treatment regimen diligently. Report any muscle-related symptoms, such as pain or weakness, immediately to your healthcare provider, especially if you have a history of muscle disorders. If you experience any signs of an allergic reaction or eosinophilic pneumonia, seek immediate medical attention. Pregnant or breastfeeding individuals should discuss the risks and benefits with their healthcare provider before using daptomycin. Never stop the medication prematurely; complete the full course as directed. Regular follow-ups and monitoring are vital to ensure the medication's efficacy and detect any potential adverse effects promptly.

1. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Protein synthesis inhibitors, and miscellaneous antibacterial agents, 12th edition, 2011, 1542 - 1543.
2. Panpharma UK Ltd, Electronic medicines compendium (EMC), [Revised on 06 Jun 2022] [ Accessed on 22nd July 2023],https://www.medicines.org.uk/emc/product/12263/smpc#gref
3. Merck Sharp & Dohme Corp., US Food and Drug Administration, [Revised on 04.03.2020] [Accessed on 22nd July 2023], /https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208385s00

The drug information on this page is not a substitute for medical advice, it is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.